| INTRODUCTION
Pelvic exenteration surgery, used to treat advanced gastrointestinal, 1,2 gynecologic, 3 and urologic malignancy, 4 is an extensive surgery that involves en bloc removal of the pelvic viscera. A total pelvic exenteration in a male includes removal of the rectum, bladder, and prostate/seminal vesicles if present. In a female patient, a total pelvic exenteration includes removal of the bladder, vagina (part or complete), uterus if present, and rectum. 5, 6 Although pelvic exenteration has significant advantages for longer disease-free and overall survival, its associated perioperative complications, including hemorrhage and infections, can negatively impact a patient's postoperative course. 7, 8 Wound infection is one of the most common postoperative complications. In patients who underwent pelvic exenteration, estimated infection rates were up to 30-43%, 7, [9] [10] [11] [12] [13] and the rate of pelvic abscess was reported to be 6-20%. [14] [15] [16] These complications can affect quality of life, impact recovery, prolong hospital length of stay (LOS), and increase the readmission rate. Prolonged hospitalization and readmissions also can increase overall healthcare costs. 17 However, few studies have assessed the risk factors for prolonged LOS in patients who undergo pelvic exenteration. We know of only such J Surg Oncol. 2018;117:529-534. wileyonlinelibrary.com/journal/jso one study, which showed that longer hospital LOS after pelvic exenteration was associated with lower body mass index (BMI). 18 The primary aim of the current study was to identify risk factors associated with longer hospital LOS following pelvic exenteration surgery. To this end, we retrospectively reviewed a large singleinstitution series of patients who underwent pelvic exenteration for gynecologic, gastrointestinal, urologic, and other cancers. 
| MATERIALS AND METHODS

| Demographic data
Patient demographic characteristics, preoperative comorbidities, cancer diagnoses, and preoperative cancer treatments for all 100 patients are listed in Table 1 . Most patients were white (n = 71), and more than half of patients were either overweight or obese (n = 64). Cardiovascular disease was the most common preoperative comorbid disease (n = 49), followed by diabetes mellitus (n = 24). About half of patients were diagnosed with gastrointestinal cancer (n = 51), and gynecologic cancer was the second most frequent cancer (n = 31). Sixty-eight patients had a cancer recurrence at the time of surgery. Of the preoperative treatments given before pelvic exenteration surgery, the most frequent was chemotherapy (n = 60), followed by radiation therapy (n = 46).
| Intraoperative data and perioperative complications
In this study, all cases were total pelvic exenterations, and 100% of patients received prophylactic antibiotics. Sixty patients had ≥3
surgical disciplines involved in their surgery. The most frequent discipline involved in the surgery was urology (n = 73), followed by gastrointestinal surgery (n = 60) and plastic surgery (n = 60). Most patients had myocutaneous flap use (n = 83). Ninety-nine patients had new ileal conduit formation, 66 had a new colostomy, and six had a new ileostomy. Postoperatively, 62 patients had an intensive care unit stay. Perioperative complications included infection (n = 44), ileus or bowel obstruction (n = 30), wound or flap dehiscence (n = 11), and anastomotic leak/fistula (n = 6). Fortyfour patients were readmitted within 3 months of surgery.
Seventy-five percent of patients had negative surgical margin.
Twenty-three patients required PMR consult, and nine patients required admission to an inpatient rehabilitation unit (Table 2 ).
| Hospital LOS
The median (IQR) hospital LOS was 15 days (10-21.5 days) (Table 2) , the mean (±standard deviation) hospital LOS was 18 (±11) days. Multicovariate regression analysis showed that the factors associated with prolonged hospital LOS were low BMI, genitourinary cancer, and sarcoma, ≥2 infections during the hospital stay, anastomotic leak/fistula during the hospital stay, physical medicine and rehabilitation consult, inpatient rehabilitation admission during the hospital stay, ≥2 services consulted during the hospital stay, and absence of gastrointestinal surgery discipline involvement during surgery (Table 3) . When other variables in Table 3 were fixed, obesity increased the mean hospital LOS by 3 days while underweight status increased the LOS by almost 12 days compared with patients who were in a normal weight range (P = 0.004).
Compared with patients with gastrointestinal cancer, patients with sarcoma had a longer hospital LOS by 12.9 days (P < 0.001), patients with genitourinary cancer had a longer hospital LOS by 2.5 days, and patients with gynecologic cancer had a shorter hospital LOS by 3.1 days.
The number of units of packed red blood cells received during surgery 
| DISCUSSION
Pelvic exenteration for curative treatment of advanced malignancies in the pelvic area is known to have significant advantages in terms of overall survival as well as disadvantages such as high rates of complications, from 32% to 84%. [19] [20] [21] These complications can affect quality of life, impact recovery, and increase overall healthcare costs. 17 In this study, we identified multiple risk factors that were associated with increased hospital LOS in patients undergoing pelvic exenteration: infections, anastomotic leak/fistula, rehabilitation consult and inpatient rehabilitation admission, and ≥2 consultation services used.
Hospital LOS was significantly prolonged in underweight patients by 12 days (P = 0.004). This result is consistent with prior studies, which showed that hospital LOS in underweight patients increased significantly after they underwent pelvic exenteration. 18 Underweight cancer patients may have malnutrition or cancer-induced cachexia, which is the result of both decreased food intake and increased energy expenditure. Cancer-related cachexia has been defined as a BMI of <20 or weight loss and sarcopenia in cancer patients. 22 Cachexia has a negative effect on the immune system, which leads to reduced lymphocyte function, impaired cellular immunity, reduced phagocyte function, and reduced killer T-cell activity. These effects may in turn be associated with postoperative complications and poorer prognosis. 7 Malnutrition in particular has been associated with a higher rate of postoperative complications. 23 Some studies have shown the usefulness of nutritional therapy to reduce healthcare costs. Although BMI is not an ideal measurement of nutritional status, it has been shown to correlate with nutritional assessments. 24 While the gold standard for nutritional assessment is still being developed, surgical teams could use BMI as a guide by aggressively applying nutritional therapy to increase patient BMI in underweight patients before surgery.
No increase in hospital LOS was observed in the overweight patients (BMI 25.0-29.9). Similar results were seen in a large study of 2258 patients who underwent major intra-abdominal surgery, 811
(35.9%) of whom were overweight; overweight status did not increase hospital LOS or increase mobility and mortality postoperatively in that study. 25 The current study showed that hospital LOS was prolonged slightly, by 3 days, in obese (BMI > 30) patients (P = 0.004). Although a previous study did not show obesity was associated with hospital LOS, 26 studies did show that obesity was associated with increased operative time, superficial wound separation, and surgical site infection. 7, 26 Our study showed that obesity and a higher number of infections were both independent risk factors for prolonged hospital LOS.
Our study is the first to compare hospital LOS after pelvic exenteration between patients with different cancer diagnoses. We showed that compared with gastrointestinal cancer, sarcoma and genitourinary cancer were associated with prolonged hospital LOS by 12.9 days and 2.5 days, respectively, whereas gynecologic cancer was associated with shorter LOS by 3.1 days (P < 0.001). These results are consistent with previous, non-comparison reports, where mean hospital LOS after pelvic exenteration was 21 days for rectal cancer patients 18 and 19-23 days for gynecologic cancer patients. 16, 27 Since studies focusing on hospital LOS after pelvic exenteration in genitourinary cancer or sarcoma populations are scarce, further study with a larger sample size is needed to confirm our finding.
Infection is reportedly the most common postoperative morbidity after pelvic exenteration. 27 Our study is the first to show that while a single postoperative infection had little effect on the hospital LOS, two and three infections prolonged hospital LOS by 10 and 32 days,
respectively. This result suggests that if infections not directly related to surgery, such as urinary tract infections or pneumonias, are prevented, the hospital LOS may be shortened.
Our study showed that anastomotic leak prolonged hospital LOS by 19 days. Anastomotic leak is inevitably associated with infection, but in this study it was an independent risk factor for LOS. In a previous study by Teixeira et al anastomotic leak prolonged hospital LOS even more profoundly, by a mean of 36 days. 28 Many patients with anastomotic leak require pelvic drain placement and intravenous antibiotic use. A consult with PMR specialists and admission to the inpatient rehabilitation unit were associated with prolonged LOS by 4 and 6 days, respectively. The likely reason for this association is that PMR consults were requested for a deconditioned patient population. When patients develop multiple complications after pelvic exenteration, their symptoms and medical condition may lead to prolonged rest, malnutrition, and significant functional decline, which may trigger a PMR consult (23% in the current study), and if they are significantly debilitated, they may require inpatient rehabilitation admission (9% in the current study) for intense rehabilitation. The utilization of at least two consult services,
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another indicator for complexity of the patients' medical/surgical illness, was also associated with longer hospital LOS.
| CONCLUSIONS
In patients who underwent pelvic exenteration for pelvic malignan- 
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